Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats

A. V. Terry, W. D. Hill, V. Parikh, D. R. Evans, J. L. Waller, S. P. Mahadik

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Rationale: In psychiatric patients, haloperidol (HAL) induces a number of adverse extrapyramidal and cognitive symptoms, which appear to be less problematic with olanzapine (OLZ). In animals, HAL may initiate a number of harmful effects on central nervous system neurons, including damage to cholinergic pathways - an effect that could be especially deleterious to those experiencing memory dysfunction. The identification of the neurobiological substrates of such effects in animal models may help to improve the algorithms used for proper drug selection especially for long-term neuroleptic use. Objectives: The aim of this study was to compare the effects of chronic (45-day and 90-day), continuous oral exposure to HAL with OLZ for effects on cognitive performance and cholinergic markers in rats. Methods: After chronic neuroleptic exposure (and a 4-day washout) spatial memory performance was measured in a water maze task, and choline acetyltransferase (ChAT) immunoreactivity was assessed with immunofluorescence staining. Results: In water maze experiments, HAL and OLZ (relative to vehicle) administered for 90 days (but not 45 days) significantly impaired learning performance (i.e., higher mean latencies across several trials to reach a hidden platform). HAL administered for 90 days was associated with impairment across a greater number of trials than OLZ and it also impaired probe trial performance, as indicated by a reduced number of crossings over the previous platform area (when compared with OLZ or vehicle). Both 45 days and 90 days of HAL treatment reduced ChAT staining in the cortex and hippocampus when compared with OLZ or vehicle. Conclusions: The results in the rat suggest that OLZ (relative to HAL) may be more desirable as an antipsychotic for patients suffering from memory dysfunction especially for those in which cholinergic deficits may already be present.

Original languageEnglish (US)
Pages (from-to)360-368
Number of pages9
JournalPsychopharmacology
Volume164
Issue number4
DOIs
StatePublished - Dec 19 2002

Fingerprint

olanzapine
Haloperidol
Cholinergic Agents
Brain
Antipsychotic Agents
Choline O-Acetyltransferase
Staining and Labeling
Neurobehavioral Manifestations
Water
Spatial Learning
Fluorescent Antibody Technique
Psychiatry
Hippocampus
Central Nervous System
Animal Models

Keywords

  • Antipsychotics
  • Cholinergic activity
  • Haloperidol
  • Olanzapine
  • Rat
  • Spatial learning performance

ASJC Scopus subject areas

  • Pharmacology

Cite this

Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. / Terry, A. V.; Hill, W. D.; Parikh, V.; Evans, D. R.; Waller, J. L.; Mahadik, S. P.

In: Psychopharmacology, Vol. 164, No. 4, 19.12.2002, p. 360-368.

Research output: Contribution to journalArticle

@article{1f364060b8f24c6f921f8ec755aa7462,
title = "Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats",
abstract = "Rationale: In psychiatric patients, haloperidol (HAL) induces a number of adverse extrapyramidal and cognitive symptoms, which appear to be less problematic with olanzapine (OLZ). In animals, HAL may initiate a number of harmful effects on central nervous system neurons, including damage to cholinergic pathways - an effect that could be especially deleterious to those experiencing memory dysfunction. The identification of the neurobiological substrates of such effects in animal models may help to improve the algorithms used for proper drug selection especially for long-term neuroleptic use. Objectives: The aim of this study was to compare the effects of chronic (45-day and 90-day), continuous oral exposure to HAL with OLZ for effects on cognitive performance and cholinergic markers in rats. Methods: After chronic neuroleptic exposure (and a 4-day washout) spatial memory performance was measured in a water maze task, and choline acetyltransferase (ChAT) immunoreactivity was assessed with immunofluorescence staining. Results: In water maze experiments, HAL and OLZ (relative to vehicle) administered for 90 days (but not 45 days) significantly impaired learning performance (i.e., higher mean latencies across several trials to reach a hidden platform). HAL administered for 90 days was associated with impairment across a greater number of trials than OLZ and it also impaired probe trial performance, as indicated by a reduced number of crossings over the previous platform area (when compared with OLZ or vehicle). Both 45 days and 90 days of HAL treatment reduced ChAT staining in the cortex and hippocampus when compared with OLZ or vehicle. Conclusions: The results in the rat suggest that OLZ (relative to HAL) may be more desirable as an antipsychotic for patients suffering from memory dysfunction especially for those in which cholinergic deficits may already be present.",
keywords = "Antipsychotics, Cholinergic activity, Haloperidol, Olanzapine, Rat, Spatial learning performance",
author = "Terry, {A. V.} and Hill, {W. D.} and V. Parikh and Evans, {D. R.} and Waller, {J. L.} and Mahadik, {S. P.}",
year = "2002",
month = "12",
day = "19",
doi = "10.1007/s00213-002-1230-z",
language = "English (US)",
volume = "164",
pages = "360--368",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats

AU - Terry, A. V.

AU - Hill, W. D.

AU - Parikh, V.

AU - Evans, D. R.

AU - Waller, J. L.

AU - Mahadik, S. P.

PY - 2002/12/19

Y1 - 2002/12/19

N2 - Rationale: In psychiatric patients, haloperidol (HAL) induces a number of adverse extrapyramidal and cognitive symptoms, which appear to be less problematic with olanzapine (OLZ). In animals, HAL may initiate a number of harmful effects on central nervous system neurons, including damage to cholinergic pathways - an effect that could be especially deleterious to those experiencing memory dysfunction. The identification of the neurobiological substrates of such effects in animal models may help to improve the algorithms used for proper drug selection especially for long-term neuroleptic use. Objectives: The aim of this study was to compare the effects of chronic (45-day and 90-day), continuous oral exposure to HAL with OLZ for effects on cognitive performance and cholinergic markers in rats. Methods: After chronic neuroleptic exposure (and a 4-day washout) spatial memory performance was measured in a water maze task, and choline acetyltransferase (ChAT) immunoreactivity was assessed with immunofluorescence staining. Results: In water maze experiments, HAL and OLZ (relative to vehicle) administered for 90 days (but not 45 days) significantly impaired learning performance (i.e., higher mean latencies across several trials to reach a hidden platform). HAL administered for 90 days was associated with impairment across a greater number of trials than OLZ and it also impaired probe trial performance, as indicated by a reduced number of crossings over the previous platform area (when compared with OLZ or vehicle). Both 45 days and 90 days of HAL treatment reduced ChAT staining in the cortex and hippocampus when compared with OLZ or vehicle. Conclusions: The results in the rat suggest that OLZ (relative to HAL) may be more desirable as an antipsychotic for patients suffering from memory dysfunction especially for those in which cholinergic deficits may already be present.

AB - Rationale: In psychiatric patients, haloperidol (HAL) induces a number of adverse extrapyramidal and cognitive symptoms, which appear to be less problematic with olanzapine (OLZ). In animals, HAL may initiate a number of harmful effects on central nervous system neurons, including damage to cholinergic pathways - an effect that could be especially deleterious to those experiencing memory dysfunction. The identification of the neurobiological substrates of such effects in animal models may help to improve the algorithms used for proper drug selection especially for long-term neuroleptic use. Objectives: The aim of this study was to compare the effects of chronic (45-day and 90-day), continuous oral exposure to HAL with OLZ for effects on cognitive performance and cholinergic markers in rats. Methods: After chronic neuroleptic exposure (and a 4-day washout) spatial memory performance was measured in a water maze task, and choline acetyltransferase (ChAT) immunoreactivity was assessed with immunofluorescence staining. Results: In water maze experiments, HAL and OLZ (relative to vehicle) administered for 90 days (but not 45 days) significantly impaired learning performance (i.e., higher mean latencies across several trials to reach a hidden platform). HAL administered for 90 days was associated with impairment across a greater number of trials than OLZ and it also impaired probe trial performance, as indicated by a reduced number of crossings over the previous platform area (when compared with OLZ or vehicle). Both 45 days and 90 days of HAL treatment reduced ChAT staining in the cortex and hippocampus when compared with OLZ or vehicle. Conclusions: The results in the rat suggest that OLZ (relative to HAL) may be more desirable as an antipsychotic for patients suffering from memory dysfunction especially for those in which cholinergic deficits may already be present.

KW - Antipsychotics

KW - Cholinergic activity

KW - Haloperidol

KW - Olanzapine

KW - Rat

KW - Spatial learning performance

UR - http://www.scopus.com/inward/record.url?scp=0036451765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036451765&partnerID=8YFLogxK

U2 - 10.1007/s00213-002-1230-z

DO - 10.1007/s00213-002-1230-z

M3 - Article

C2 - 12457265

AN - SCOPUS:0036451765

VL - 164

SP - 360

EP - 368

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -